WILMINGTON, Mass., July 17, 2014 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB:IMSC), a high technology supplier of
systems and sensors for homeland security and defense markets,
today stated that it has shipped over $550,000 in previously unannounced orders of
QS-H150 and QS-B220s to multiple customers in North America, Europe, Middle
East, and Africa. Customers
for the handheld and desktop explosives trace detectors include a
major international logistics corporation, a construction company,
an airport, and the embassy of a foreign nation. The systems will
be used for building security and for the screening of air cargo,
and airline passengers and baggage.
"The regulatory certifications we have received so far for our
products have established a strong foothold for the Company in
aviation security. Adding cargo, passenger, and baggage screening
to our existing markets like building security, subways, and
critical infrastructure has been an important part of our ability
to significantly increase orders received as compared to the the
previous year. We anticipate that success in the approval efforts
we have underway at the moment will strongly accelerate this
trend," stated Implant Sciences' Vice President of Sales and
Marketing, Dr. Darryl Jones.
About the QS-H150 Handheld Explosives Trace Detector
The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology,
providing fast, accurate detection of trace amounts of a wide
variety of military, commercial, and homemade explosives. Built
with no radioactive materials and featuring a low-maintenance,
self-calibrating, and self-clearing design, the QS-H150 provides
very high levels of operational availability. The QS-H150 has been
proven to perform well in a wide variety of temperatures and
challenging environments, from humid jungles to dry, sand swept
deserts.
About the QS-B220 Desktop Explosives and Drugs Trace
Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly
detect and identify trace amounts of a wide variety of military,
commercial, and homemade explosives as well as illicit drugs. With
significantly lower maintenance requirements than competing
systems, the QS-B220 can be deployed for a much lower total cost of
ownership than other approved products. Featuring a radioactive
material-free design, push-button maintenance and diagnostics, and
a patented inCal™ internal automatic calibration system, the
QS-B220 brings new levels of performance and convenience to desktop
trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. Implant
Sciences is only the third manufacturer, and the sole
American-owned company, to currently have an ETD system named as a
Qualified Product by the US Transportation Security Administration.
The Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., STAC in France, the German
Ministry of the Interior, and the Ministry of Public Safety in
China. It also received a GSN 2013
Homeland Security Award for "Best Explosives Detection
Solution". All Implant Sciences products are recognized as
Qualified Anti-Terrorism Technologies by the Department of Homeland
Security. For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking
statements," as that term is defined in the Private Securities
Litigation Reform Act of 1995. Such statements are based on
management's current expectations and are subject to risks and
uncertainties that could cause the Company's actual results to
differ materially from the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the risks that
our explosives detection products and technologies (including any
new products we may develop) may not be accepted by the
Transportation Security Administration or by other U.S. or foreign
government and law enforcement agencies or commercial consumers of
security products; economic, political and other risks associated
with international sales and operations could adversely affect our
sales; our business is subject to intense competition and rapid
technological change, and our success will depend on our ability to
develop and introduce new products; and other risks and
uncertainties described in our filings with the Securities and
Exchange Commission, including our most recent Forms 10-K, 10-Q and
8-K. Such statements are based on management's current expectations
and assumptions which could differ materially from the
forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
SOURCE Implant Sciences Corporation